Daniel DeAngelo, MD, PhD, discusses triggers for treatment initiation and the use of ruxolitinib in patients with high-risk or symptomatic myelofibrosis, as well as the role of stem cell transplantation in this patient.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
Ещё видео!